Drugs / ANV600
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06470763 | Jul 2024 → Jun 2026 | neoplasm | Anaveon AG | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-28 | Anaveon AG | Results Anaveon Reports Clinical Benefit of ANV600, an IL-2R-βγ agonist, in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio anaveon.com ↗
A complete response (CR) was observed in a patient with NSCLC (non-small cell lung cancer) previously progressing on CPI and treated with ANV600 monotherapy at 120 µg/kg Q2W. |
| 2026-05-11 | Anaveon AG | Results Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio anaveon.com ↗
Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system for the treatment of autoimmune and inflammatory diseases, today announced that new clinical data from its legacy oncology asset ANV600 (sunekafusp alpha) will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANV600 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06470763 ↗ |
| Route | Intravenous | “ANV600 administered by intravenous (IV) infusion” NCT06470763 ↗ |